On Jan. 12, 2026,  AbbVie announced a voluntary agreement with the Trump administration to further advance access and affordability for Americans while protecting and investing in U.S. pharmaceutical innovation.

The company will provide low prices in Medicaid while pledging $100 billion in U.S.-based research and development and capital investments, including manufacturing, over the next decade. AbbVie will also expand direct-to-patient offerings through TrumpRx for medicines used by millions of Americans, including ALPHAGAN®, COMBIGAN®, HUMIRA® and SYNTHROID®.

AbbVie’s agreement, which addresses all four of the President’s drug pricing priorities, was enabled by the Trump administration providing exemption from tariffs and future price mandates, and the government’s continued efforts to ensure global prices reflect the full value of U.S. medical innovation. Further terms of this agreement remain confidential.